婴儿和儿童常规使用四价脑膜炎球菌白喉类毒素结合疫苗(MenACWY-D)的上市后安全性监测研究
在美国北加州凯撒医疗集团开展两项观察性回顾性研究,评估2-10岁儿童和9-23月龄婴幼儿常规接种MenACWY-D后的安全性。采用自身对照风险区间设计,比较接种后0-30天与31-60/31-180天(儿童)或31-75天(婴幼儿)的不良结局发生率。结论为接种未发现新的安全性问题,但研究样本量小,检测罕见事件能力有限。
要点
- 2-10岁儿童中仅蜂窝织炎/脓肿发生率显著升高(风险区间2例 vs 对照区间0例,IRR不可评估,95%CI:1.42,NE),经病历审查认为与接种无关。
- 9-23月龄婴幼儿中接种后无任何结局显著升高,且无住院病例。
- 两项研究在3年入组及随后6个月监测期间均未观察到死亡。
核心结论
- 婴儿和低龄儿童接种MenACWY-D疫苗未发现新的安全性问题,但这些小样本研究检测罕见或不常见安全性事件的能力有限。
研究设计与样本
- 在美国北加州凯撒医疗集团(KPNC)开展两项观察性回顾性研究,分别纳入2-10岁儿童(2007年10月至2010年10月)和9-23月龄婴幼儿(2011年6月至2014年6月)。
- 采用自身对照风险区间设计,计算接种后风险区间(0-30天)与较远对照区间(31-60天和31-180天[儿童]或31-75天[婴幼儿])结局的发生率比(IRR)。
- 监测所有受试者的非计划住院、急诊就诊和选定的门诊结局(特定神经系统疾病、超敏反应和新发自身免疫病),随访至接种后6个月(取决于研究)。
主要发现
- 共有1421名2-10岁儿童和116名9-23月龄婴幼儿接种了MenACWY-D;约30%的2-10岁儿童和67%的9-23月龄婴幼儿被认为脑膜炎球菌病风险增加。
- 2-10岁儿童中,接种后第5天有1例因发热住院,被认为可能与接种相关;唯一显著升高的结局为蜂窝织炎/脓肿(风险区间2例 vs 对照区间0例;IRR不可评估[NE],95%CI:1.42,NE),经病历审查后2例被认为与接种无关。
- 9-23月龄婴幼儿中,接种后无任何结局显著升高,且无住院病例。
- 两项研究在3年入组及随后6个月监测期间均未观察到死亡。
局限性
- 这些小型研究检测罕见或不常见安全性事件的能力有限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Menactra® vaccine (MenACWY-D) was licensed in the United States in 2005 for persons 11-55 years of age, in 2007 for children 2-10 years of age, and in 2011 for infants/toddlers 9-23 months of age. We conducted two studies at Kaiser Permanente Northern California (KPNC), an integrated health care organization, to assess the safety of MenACWY-D in 2-10-year-olds and 9-23-month-olds receiving the vaccine during routine clinical care. METHODS: We conducted observational, retrospective studies of MenACWY-D in 2-10-year-olds (October 2007-October 2010) and in 9-23-month-olds (June 2011-June 2014). We monitored all subjects for non-elective hospitalizations, emergency department visits, and selected outpatient outcomes (specified neurological conditions, hypersensitivity reactions and new-onset autoimmune diseases) up to 6 months after vaccination, depending on the study. Using a self-control risk-interval design, we calculated incidence rate ratios (IRRs) comparing outcomes during the post-vaccination risk interval (0-30 days) with those during more remote post-vaccination comparison intervals (31-60 and 31-180 days [children] or 31-75 days [infants/toddlers]). RESULTS: There were 1421 children aged 2-10 years and 116 infants/toddlers aged 9-23 months who received MenACWY-D. Approximately 30% of the 2-10-year-olds and 67% of the 9-23-month-olds were considered at increased risk of meningococcal disease. Among 2-10-year-olds, there was 1 hospitalization on post-vaccination day 5 for fever, which was considered possibly related to vaccination. The only significantly elevated outcome among 2-10-year-olds was cellulitis/abscess (2 cases occurred during the risk interval versus 0 during comparison interval; IRR not evaluable [NE], 95% CI: 1.42, NE). After medical record review, the 2 cases were considered unrelated to vaccination. Among 9-23-month-olds, no outcomes were significantly elevated after vaccination and there were no hospitalizations. There were no deaths observed during the three-year accrual and subsequent six-month surveillance period for either study. CONCLUSIONS: Immunization of infants and young children with MenACWY-D vaccine was not associated with any new safety concerns; however, these small studies had limited power to detect rare or uncommon safety events. ClinicalTrials.gov Identifiers are NCT00728260 and NCT01689155.
引用
- Hansen J, Zhang L, Eaton A, et al. Post-licensure safety surveillance study of routine use of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D) in infants and children. Vaccine. 2018. PMID: 29550195. doi:10.1016/j.vaccine.2018.02.107
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。